Elsevier Inc.

SHERPA: Unknown

People

  1. Lee
    Lee
  2. Giralt
    Giralt
  3. Mulhall
    Mulhall
  4. Perales
    Perales
  5. Yorke
    Yorke
  6. Wolden
    Wolden
  7. Rusch
    Rusch
  8. Yamada
    Yamada
  9. Zhang
    Zhang
  10. Travis
    Travis

Groups

  1. Department of Medicine (4218)
  2. Surgery (2710)
  3. Survivorship Research (2394)
  4. Solid Tumor Oncology Division (2240)
  5. Radiation Oncology, Department of (2047)
  6. GSK Faculty (1884)
  7. Center for Hematologic Malignancies (1669)
  8. Hematologic Malignancies, Division of (1531)
  9. Sloan Kettering Institute Faculty (1376)
  10. Medical Physics (1209)
Search Within
Formats
  1. Journal Article (6733)
  2. Meeting Abstract (4312)
  3. Review (631)
  4. Book Section (542)
  5. Editorial (253)
  6. Conference Paper (132)
  7. Correspondence (92)
  8. Guidelines (85)
  9. Research Letter (33)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4218)
  2. Surgery (2710)
  3. Survivorship Research (2394)
  4. Solid Tumor Oncology Division (2240)
  5. Radiation Oncology, Department of (2047)
  6. GSK Faculty (1884)

More Groups

People
  1. Nancy Lee (413)
  2. Michael Zelefsky (401)
  3. Sergio Giralt (386)
  4. John Mulhall (381)
  5. Miguel-Angel Perales (303)
  6. Andreas Rimner (292)

More People

Years
  1. 2026 (3)
  2. 2025 (397)
  3. 2024 (708)
  4. 2023 (680)
  5. 2022 (745)
  6. 2021 (665)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2629)
  2. Journal of Thoracic Oncology (973)
  3. Biology of Blood and Marrow Transplantation (815)
  4. European Journal of Cancer (529)
  5. Journal of Sexual Medicine (440)
  6. Clinical Lymphoma, Myeloma and Leukemia (402)

More Publications

Results (12842)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real world experience of talquetamab in relapsed refractory myeloma, first report from the IMWG Consortium
    Meeting Abstract

    Janakiram, M.; Tan, C.; Popat, R.; Kastritis, E.; Martínez-Lopez, J.; Shekarkhand, T.; Bansal, R.; De Menezes Silva Corraes, A.; de la puerta, M. C.; Sáez Marín, A. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Bispecific antibodies improve outcomes in patients with relapsed or refractory multiple myeloma after CAR-T cell therapy
    Meeting Abstract

    Merz, M.; Dima, D.; Hashmi, H.; Mueller, F.; Ahmed, N.; Rathje, K.; Davis, J.; Holderried, T.; Vucinik, V.; Kharbouti, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of ABBV-383, a BCMA bispecific antibody, in black patients with relapsed/refractory multiple myeloma: A subgroup analysis of a phase 1 trial
    Meeting Abstract

    D'Souza, A.; Rodriguez-Valdes, C.; Kumar, S.; Chung, A.; Tuchman, S.; Safah, H.; Weisel, K.; Teipel, R.; Korde, N.; Vij, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Genomic landscape of IgM MGUS and stable versus progressive asymptomatic Waldenström macroglobulinemia patients
    Meeting Abstract

    Bagratuni, T.; Theologi, O.; Vlachos, C.; Aktypi, F.; Maclachlan, K.; Kollias, I.; Mavrianou-Koutsoukou, N.; Liacos, C.; Papadimou, A.; Taouxi, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Interim results of a phase 2 trial of isatuximab-lenalidomide for patients with High-Risk Smoldering Multiple Myeloma
    Meeting Abstract

    Thomas, S.; Manasanch, E.; Korde, N.; Lee, H.; Jagannath, S.; Becnel, M.; Kaufman, G.; Patel, K.; Iyer, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)
    Meeting Abstract

    Costa, A.; Dhakal, B.; Hultcrantz, M.; Bal, S.; Chuah, H.; Kaufman, J. L.; Kazandjian, D.; Nathwani, N.; Royle, G.; Sborov, D. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save